A clearance, a strong pilot and a roomful of clinical advocates used to be enough to set a Health company on its way. They no longer are. Across digital health, medtech and diagnostics, the same thing keeps happening: the early customers love the product, the published evidence holds up, the next sales cycle stalls anyway.

Buyers have changed. A self-insured employer cutting its vendor list from twenty to eight wants outcomes data its CFO can underwrite. A hospital value-analysis committee inside a Vizient or Premier contract weighs your device against three others and asks for a health-economic case it can defend in front of its own board. A Medicare administrative contractor decides whether the diagnostic gets a coverage code, and the company's revenue model with it.

None of these conversations is the conversation the company was built to have.

The work that closes the gap is the part most companies treat as four separate workstreams. Clinical builds the evidence. Commercial chases the next contract. Product ships features and races whichever foundation model is closest to the category. Marketing reworks the website. The board reads four reports. The buyer reads one company, and the renewal turns on whether the four hold together. The work is to make them hold together.

To rebuild the layer between the technology and the buyer as a single piece, deliberately, where it had been built in fragments. This is the layer we work on. With leadership, alongside the people already running the company. The first conversation is usually less about a programme and more about understanding the shape of that layer, and where the highest-leverage move actually sits.